The study explores how menopause and postmenopausal hormone therapy (PHT) influence the risk of metabolic syndrome in women. It discusses potential benefits of PHT in reducing risks related to glucose metabolism, lipid profiles, and cardiovascular health. The findings suggest a role for individualized postmenopausal care, particularly considering metabolic risks.
The study titled “Depression and the menopause: why antidepressants are not enough?” (Menopause International, 2009, PMID: 19465674) explores the link between menopause and depression, highlighting that postmenopausal depression is often more severe, insidious, and resistant to conventional antidepressants. Key findings suggest that combining hormone therapy (HT) with antidepressants results in
The article “Disorders of Orgasm in Women” by Cindy M. Meston et al., published in the Journal of Sexual Medicine (PMID: 16422985), reviews Female Orgasmic Disorder (FOD), a condition characterized by persistent or recurrent delay or absence of orgasm following normal sexual excitement, leading to distress or interpersonal difficulty. The
The article “Acute consequences of the menopausal transition: the rise of common menopausal symptoms” by Clarisa R. Gracia and Ellen W. Freeman, published in Endocrinology and Metabolism Clinics of North America (PMID: 15501640), reviews the onset and prevalence of menopausal symptoms such as hot flashes, night sweats, and mood changes,
This clinical trial examined how oral progesterone absorption is influenced by formulation, specifically particle size and vehicle type. Seven subjects received a 200 mg dose of progesterone in different formulations: plain milled, micronized, plain milled in oil, micronized in oil, and micronized in enteric-coated capsules. Serum progesterone levels were measured
